ATE486125T1 - Verabreichung teilgereifter dendritischer zellen in vitro zur behandlung von tumoren - Google Patents

Verabreichung teilgereifter dendritischer zellen in vitro zur behandlung von tumoren

Info

Publication number
ATE486125T1
ATE486125T1 AT03790358T AT03790358T ATE486125T1 AT E486125 T1 ATE486125 T1 AT E486125T1 AT 03790358 T AT03790358 T AT 03790358T AT 03790358 T AT03790358 T AT 03790358T AT E486125 T1 ATE486125 T1 AT E486125T1
Authority
AT
Austria
Prior art keywords
dendritic cells
tumor
cells
partially matured
administration
Prior art date
Application number
AT03790358T
Other languages
English (en)
Inventor
Marnix Bosch
Original Assignee
Northwest Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwest Biotherapeutics Inc filed Critical Northwest Biotherapeutics Inc
Application granted granted Critical
Publication of ATE486125T1 publication Critical patent/ATE486125T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/50—Colon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/72—Undefined extracts from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT03790358T 2002-12-06 2003-12-05 Verabreichung teilgereifter dendritischer zellen in vitro zur behandlung von tumoren ATE486125T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43126702P 2002-12-06 2002-12-06
PCT/US2003/038672 WO2004053072A2 (en) 2002-12-06 2003-12-05 Administration of dendritic cells partially matured in vitro for the treatment of tumors

Publications (1)

Publication Number Publication Date
ATE486125T1 true ATE486125T1 (de) 2010-11-15

Family

ID=32507696

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03790358T ATE486125T1 (de) 2002-12-06 2003-12-05 Verabreichung teilgereifter dendritischer zellen in vitro zur behandlung von tumoren

Country Status (19)

Country Link
US (2) US20060057120A1 (de)
EP (2) EP1567155B1 (de)
JP (2) JP4859169B2 (de)
KR (1) KR101144196B1 (de)
CN (2) CN102600461B (de)
AT (1) ATE486125T1 (de)
AU (2) AU2003293411B2 (de)
BR (1) BRPI0317064B8 (de)
CA (1) CA2509058A1 (de)
DE (1) DE60334725D1 (de)
DK (1) DK1567155T3 (de)
ES (1) ES2354944T3 (de)
HK (1) HK1082180A1 (de)
IL (1) IL169002A (de)
MX (1) MXPA05006042A (de)
PL (1) PL377209A1 (de)
PT (1) PT1567155E (de)
RU (1) RU2348418C2 (de)
WO (1) WO2004053072A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1567155E (pt) * 2002-12-06 2011-01-28 Northwest Biotherapeutics Inc Administração de células dendríticas parcialmente amadurecidas in vitro para o tratamento de tumores
US20070134273A1 (en) * 2004-02-10 2007-06-14 Francois Romagne Composition and method for the treatment of carcinoma
US20060216269A1 (en) * 2004-09-17 2006-09-28 Kenichiro Hasumi Dendritic cell tumor injection (DCTI) therapy
US8076132B2 (en) * 2004-09-17 2011-12-13 Hasumi International Research Foundation Dendritic cell tumor injection (DCTI) therapy
WO2006095330A2 (en) * 2005-03-10 2006-09-14 Yeda Research And Development Co. Ltd. Methods and immunogenic cell preparations for treating antigen-associated diseases
WO2007001200A1 (fr) * 2005-06-23 2007-01-04 Obschestvo S Ogranichennoi Otvetsvennostyu 'rusgen' Cellules dendritiques matures chargees d'un polylysat de tumeurs, et vaccin antitumoral a base desdites cellules
AR060424A1 (es) * 2007-04-11 2008-06-18 Consejo Nac Invest Cient Tec Lineas celulares , composiciones para el tratamiento de melanomas que las comprenden procedimientos para preparar las composiciones y metodos de tratamiento
WO2008133595A1 (en) * 2007-04-26 2008-11-06 Newbiomed Pika Pte Ltd Compositions and methods for stimulating an immune response in-vivo and in-vitro
WO2008151389A1 (en) * 2007-06-15 2008-12-18 Macfarlane Burnet Institute For Medical Research And Public Health Limited Chemically modified macromolecules
EP2072617A1 (de) * 2007-12-12 2009-06-24 Trimed Biotech GmbH Verfahren zur Herstellung dendritischer Zellen
EP3293255A1 (de) * 2008-03-27 2018-03-14 Asterias Biotherapeutics, Inc. Differenzierung von pluripotenten primatenstammzellen und zellen der hämatopoietischen abstammungslinie
US8679834B2 (en) * 2009-07-09 2014-03-25 TiGenix S.A.U Methods and compositions for use in cellular therapies
EP2534242B1 (de) * 2010-02-10 2016-04-20 Immunicum AB Verbesserte zusammensezung zur inhibierung der tumorzellproliferation
RU2530523C2 (ru) * 2012-03-29 2014-10-10 Олег Борисович Егоров Способ противоопухолевой иммунотерапии
SG11201510552WA (en) 2012-06-27 2016-01-28 Hasumi Internat Res Foundation Therapy and method for intratumorally introducing cytotoxic t lymphocyte and/or nkt cell with anti-tnf and/or anti-il-10
GB201300049D0 (en) * 2013-01-03 2013-02-20 Transimmune Ag Method for obtaining immuno-stimulatory dendritic cells
EP3065772A4 (de) 2013-11-05 2017-09-13 Cognate Bioservices, Inc. Kombinationen aus checkpoint-inhibitoren und therapeutika zur behandlung von krebs
GB201413665D0 (en) * 2014-07-03 2014-09-17 Transimmune Ag And Yale University Method for obtaining globally activated monocytes
CN107849537A (zh) * 2015-06-30 2018-03-27 西北生物治疗药物公司 诱发改善的或增加的抗肿瘤免疫应答的经最佳活化的树突细胞
DK3350318T3 (da) * 2015-09-15 2022-07-11 Northwest Biotherapeutics Inc Fremgangsmåder relateret til aktiverede dendritiske cellesammensætninger til individer med fremskredne cancersygdomme
KR101749165B1 (ko) * 2016-06-07 2017-06-23 충남대학교산학협력단 Rv2299c 또는 Rv2299c와 ESAT-6 융합한 단백질을 포함하는 수지상 세포의 성숙화 촉진용 조성물
WO2018160666A1 (en) * 2017-02-28 2018-09-07 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Short-term activated dc1s and methods for their production and use
GB201711379D0 (en) * 2017-07-14 2017-08-30 Univ Cape Town Maturation of dendritic cells
CN109957548B (zh) * 2017-12-26 2022-03-18 上海尚泰生物技术有限公司 一种基因修饰的树突状细胞疫苗
GB2624871A (en) * 2022-11-29 2024-06-05 Alv B As Process for preparing a population of dendritic cells and immunotherapy using the same

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69333433T2 (de) 1992-04-01 2004-12-02 The Rockefeller University Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
US5788963A (en) * 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
US6797488B1 (en) * 1997-12-08 2004-09-28 Beth Israel Deaconess Medical Center Methods of producing anti-angiogenic proteins
CN1330557A (zh) * 1998-09-15 2002-01-09 匹兹堡大学联邦系统高等教育 原位注射具有基因上增进细胞因子表达的抗原呈递细胞
CN1321189A (zh) * 1998-10-02 2001-11-07 三菱化学株式会社 细胞性免疫的诱导方法以及被诱导了细胞免疫的细胞
US6649158B1 (en) * 1998-10-15 2003-11-18 Canji, Inc. Methods and compositions to induce antitumor response
US6558951B1 (en) * 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
WO2000061132A1 (en) * 1999-04-14 2000-10-19 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions containing immunotoxins and agents that inhibit dendritic cell maturation for inducing immune tolerance to a graft
US20030108527A1 (en) * 1999-12-28 2003-06-12 Tsukasa Seya Maturation-promoting agent for immature dendrtic cells
JP2002069001A (ja) * 2000-08-29 2002-03-08 Asahi Kasei Corp 樹状細胞を主成分とする細胞ワクチン
US20020094545A1 (en) 2000-11-30 2002-07-18 Harris Paul E. Growth of human dendritic cells for cancer immunotherapy in closed system using microcarrier beads
AU2002326463A1 (en) * 2001-07-25 2003-02-17 Northwest Biotherapeutics, Inc. Methods and apparatus for enrichment and culture of monocytic dendritic cell precursors
WO2003022215A2 (en) * 2001-09-06 2003-03-20 Northwest Biotherapeutics, Inc. Compositions and methods for priming monocytic dendritic cells and t cells for th-1 response
PT1567155E (pt) * 2002-12-06 2011-01-28 Northwest Biotherapeutics Inc Administração de células dendríticas parcialmente amadurecidas in vitro para o tratamento de tumores
MXPA05009178A (es) * 2003-02-27 2006-03-08 Northwest Biotherapeutics Inc Generacion de celulas dendriticas a partir de celulas precursoras dendriticas monociticas con gm-csf en ausencia de citocinas adicionales.

Also Published As

Publication number Publication date
JP2006510667A (ja) 2006-03-30
RU2005121256A (ru) 2006-02-10
WO2004053072A3 (en) 2005-06-16
JP4859169B2 (ja) 2012-01-25
EP2260861A1 (de) 2010-12-15
CN102600461A (zh) 2012-07-25
IL169002A (en) 2015-01-29
US20060057120A1 (en) 2006-03-16
JP5707284B2 (ja) 2015-04-30
AU2003293411A1 (en) 2004-06-30
EP1567155B1 (de) 2010-10-27
RU2348418C2 (ru) 2009-03-10
ES2354944T3 (es) 2011-03-21
PL377209A1 (pl) 2006-01-23
KR101144196B1 (ko) 2012-05-21
MXPA05006042A (es) 2005-09-21
DE60334725D1 (de) 2010-12-09
BR0317064A (pt) 2005-10-25
BRPI0317064B1 (pt) 2020-11-03
CN102600461B (zh) 2017-07-14
HK1082180A1 (en) 2006-06-02
BRPI0317064B8 (pt) 2021-05-25
CN1738619B (zh) 2012-04-18
EP1567155A4 (de) 2006-12-13
US20120251561A1 (en) 2012-10-04
WO2004053072A2 (en) 2004-06-24
CA2509058A1 (en) 2004-06-24
KR20050084189A (ko) 2005-08-26
AU2003293411B2 (en) 2010-10-28
JP2011246493A (ja) 2011-12-08
EP1567155A2 (de) 2005-08-31
AU2011200352A1 (en) 2011-02-17
DK1567155T3 (da) 2011-02-14
CN1738619A (zh) 2006-02-22
PT1567155E (pt) 2011-01-28
AU2011200352B2 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
ATE486125T1 (de) Verabreichung teilgereifter dendritischer zellen in vitro zur behandlung von tumoren
Okamoto et al. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation
Bilsborough et al. Mucosal CD8α+ DC, with a plasmacytoid phenotype, induce differentiation and support function of T cells with regulatory properties
Ito et al. TLR9 regulates the mycobacteria-elicited pulmonary granulomatous immune response in mice through DC-derived Notch ligand delta-like 4
Han et al. Vitamin E supplementation increases T helper 1 cytokine production in old mice infected with influenza virus
Lazarski et al. IL-4 attenuates Th1-associated chemokine expression and Th1 trafficking to inflamed tissues and limits pathogen clearance
Handel-Fernandez et al. Down-regulation of IL-12, not a shift from a T helper-1 to a T helper-2 phenotype, is responsible for impaired IFN-gamma production in mammary tumor-bearing mice.
CA2483012A1 (en) Oligonucleotide compositions and their use for the modulation of immune responses
Salio et al. Dendritic cell maturation is induced by mycoplasma infection but not by necrotic cells
ES2113980T3 (es) Ligandos solubles para cd40.
Hotz et al. Reprogramming of TLR7 signaling enhances antitumor NK and cytotoxic T cell responses
UA85371C2 (ru) Модифицированный вирус коровьей оспы ankara для вакцинации новорожденных
ATE389712T1 (de) Krebs immuntherapie mit semi-allogenen zellen
Habibi et al. Cytokine gene expression in healing and non‐healing cases of cutaneous leishmaniasis in response to in vitro stimulation with recombinant gp63 using semi‐quantitative RT–PCR
CN105007930B (zh) 用于治疗疾病的同种异体自噬体富集组合物
DE60137146D1 (de) Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten
Zeng et al. Natural killer cells play a key role in the antitumor immunity generated by chaperone‐rich cell lysate vaccination
JP2019509264A (ja) ワクチンアジュバントとしての間葉系幹細胞及びそれを使用するための方法
MX2023001622A (es) Celulas dendriticas optimamente activadas que inducen una respuesta inmunologica antitumoral mayor o mejorada.
ATE381942T1 (de) Mittel zur behandlung von infektionen mit leishmanien
Karsten et al. Biologic meshes and synthetic meshes in cancer patients: a double-edged sword: differences in production of IL-6 and IL-12 caused by acellular dermal matrices in human immune cells
YU40796A (sh) Preparati i postupci za tretiranje obolenja koja izazivaju t ćelije
Saito et al. Characterization of the indirect antitumor effect of γ-interferon using ascites-associated macrophages in a human tumor clonogenic assay
Enioutina et al. The induction of systemic and mucosal immunity to protein vaccines delivered through skin sites exposed to UVB
DE60135232D1 (de) Nukleinsäure und korrespondierendes protein 85p1b3, nützlich zur behandlung und detektion von krebserkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1567155

Country of ref document: EP